Fig. 2: Phenotyping hypertrophic cardiomyopathy in MLP-deficient hESC-CMs. | Cell Death & Disease

Fig. 2: Phenotyping hypertrophic cardiomyopathy in MLP-deficient hESC-CMs.

From: MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling

Fig. 2

a Immunostaining of sarcomeric α-actinin (green) and cTnT (red) demonstrates sarcomeric disarray in MLP KO CMs at day 30. Scale bar, 50 μm. b Compared with WT hESC-CMs (n = 189), a significant higher percentage of MLP KO hESC-CMS (n = 191) showed disorganized sarcomeric α-actinin staining pattern in greater than one fourth of the total cellular area. c Images of α-actinin/DAPI-immunostained hESC-CMs and d quantification of mono-, bi-, and multi-nucleation in WT (n = 267) and MLP KO (n = 259) hESC-CMs. Scale bar, 50 μm. e, f Calibration of forward scatter (FSC; 10,000 cells/sample, n = 3) showing an increased cellular size beginning 22 days post cardiac differentiation in MLP KO CMS. f Results are presented as means ± S.E.M. of three independent experiments. *P < 0.05; **P < 0.01; ns, not significant, unpaired two-sided Student’s t test

Back to article page